Keytruda improves OS for high-risk early-stage TNBC in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III KEYNOTE-522 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its overall survival endpoint, in combination with chemotherapy as pre-operative treatment and then continuing as a single agent after surgery for the treatment of patients with high-risk early-stage triple-negative breast cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, plus Keytruda (pembrolizumab) improved recurrence-free survival and distant metastasis-free survival as an adjuvant treatment for patients with completely resected stage 2B-4 melanoma, according to results of the phase III INTerpath-001 trial. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login